摘要：2025年5月30日至6月3日，一年一度的美国临床肿瘤学会（ASCO）年会于美国芝加哥隆重举行。作为全球肿瘤学领域规模最大、最具影响力的学术盛会之一，ASCO年会现场汇聚全球肿瘤领域顶尖专家，共同探讨癌症治疗的前沿创新突破与未来发展方向。

2025年5月30日至6月3日，一年一度的美国临床肿瘤学会（ASCO）年会于美国芝加哥隆重举行。作为全球肿瘤学领域规模最大、最具影响力的学术盛会之一，ASCO年会现场汇聚全球肿瘤领域顶尖专家，共同探讨癌症治疗的前沿创新突破与未来发展方向。

相关研究涉及的创新药包括8款已上市创新产品：注射用卡瑞利珠单抗（艾瑞卡）、甲磺酸阿帕替尼片（艾坦）、马来酸吡咯替尼片（艾瑞妮）、羟乙磺酸达尔西利片（艾瑞康）、阿得贝利单抗注射液（艾瑞利）、氟唑帕利胶囊（艾瑞颐）、注射用瑞康曲妥珠单抗（艾维达，研发代号：SHR-A1811）、苹果酸法米替尼胶囊（艾比特），以及7款未上市创新产品：抗PD-L1/TGF-βRⅡ双抗瑞拉芙普-α（SHR-1701）、IL-15融合蛋白SHR-1501、双特异性抗体SHR-2017、全人源抗CTLA-4单克隆抗体SHR-8068、抗体偶联药物（ADC）SHR-1826、SHR-A1912、SHR-A2102。2类新药盐酸伊立替康脂质体注射液（Ⅱ）（越优力）及国内首仿药昂丹司琼口溶膜（艾其速）各有1项研究入选。

9项创新药研究成果入选口头报告和快速口头报告

中国学者携创新药研究再发中国强音！

本届ASCO年会中，由中山大学肿瘤防治中心张阳教授、上海市胸科医院钟润波教授、复旦大学附属肿瘤医院季冬梅教授、上海长征医院杨诚教授分别对4项创新产品的相关研究进行口头报告，包括SHR-1826治疗实体瘤、SHR-A2102治疗实体瘤、瑞康曲妥珠单抗（SHR-A1811）治疗唾液腺癌，以及卡瑞利珠单抗联合阿帕替尼治疗脊索瘤。

同时，复旦大学附属肿瘤医院邵志敏教授、河南省肿瘤医院闫敏教授、复旦大学附属肿瘤医院李婷教授、湖南省肿瘤医院李亚军教授、北京大学肿瘤医院毛丽丽教授分别带来快速口头报告，内容涉及达尔西利治疗乳腺癌、瑞康曲妥珠单抗（SHR-A1811）治疗乳腺癌、阿得贝利单抗治疗乳腺癌、SHR-A1912治疗淋巴瘤以及卡瑞利珠单抗联合阿帕替尼治疗黑色素瘤。

此次中国学者携9项研究成果成功入选2025年ASCO口头报告和快速口头报告，又一次展现了其在全球恶性肿瘤治疗领域的“中国智慧”，彰显了中国创新药企恒瑞医药在创新药物研发领域的深厚积累与卓越实力，在不断提升全球学术竞争力的同时，为我国医药创新高质量发展提供重要例证。

# 01摘要号：106

Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors.

作者：中山大学肿瘤防治中心 张阳

报告时间：2025年6月2日 10:21-10:33（北京时间6月2日 23:21-23:33）

# 02摘要号：107

Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors.

作者：上海市胸科医院 钟润波

报告时间：2025年6月2日 10:33-10:45（北京时间6月2日 23:33-23:45）

# 03摘要号：6006

SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results.

作者：复旦大学附属肿瘤医院 季冬梅

报告时间：2025年5月31日15:15-15:27（北京时间6月1日 04:15-04:27）

# 04摘要号：11503

Camrelizumab plus apatinib in patients with advanced or refractory chordoma: Asingle-arm, open-label, phase 2 trial.

作者：上海长征医院 杨诚

报告时间：2025年6月1日10:45-10:57（北京时间6月1日 23:45-23:57）

# 05摘要号：515

Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.

作者：复旦大学附属肿瘤医院 邵志敏

报告时间：2025年6月1日09:00-09:06（北京时间6月1日 23:45-23:57）

# 06摘要号：1017

HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial.

作者：河南省肿瘤医院 闫敏

报告时间：2025年5月30日15:21-15:27（北京时间5月31日 04:21-04:27）

# 07摘要号：1018

A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.

作者：复旦大学附属肿瘤医院 李婷

报告时间：2025年5月30日15:27-15:33（北京时间5月31日 04:27-04:33）

# 08摘要号：7013

CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.

作者：湖南省肿瘤医院 李亚军

报告时间：2025年5月31日08:36-08:42（北京时间5月31日 21:36-21:42）

# 09摘要号：9512

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial.

作者：北京大学肿瘤医院 毛丽丽

报告时间：2025年6月2日10:15-10:21（北京时间6月2日 23:15-23:21）

（上下滑动查看更多）

消化系统肿瘤领域：

PD-（L）1抑制剂多维探索，共谱崭新篇章

在消化系统肿瘤领域，以卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、SHR-8068为代表的创新药研究硕果累累，共有 30 项相关研究入选本届 ASCO 年会，其中仅卡瑞利珠单抗占据 21 项研究，全方位、多维度地展现出其卓越的治疗效果与显著特点，续写着国产 PD-1 抑制剂在消化系统肿瘤治疗领域的崭新篇章。

此外，在肺癌领域收获亮眼成绩的阿得贝利单抗也在消化系统肿瘤领域积极探索新的适应症，5项入选研究涉及肝癌、胆管癌、胰腺癌等。新老药物前沿探索成果的持续更新有望为消化系统肿瘤患者带来更多获益！

# 01摘要号：2597

Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial.

作者：河北医科大学第四医院 王军

# 02摘要号：4038

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II clinical trial.

作者：河南省肿瘤医院 侯新芳

# 03摘要号：4042

Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study.

作者：江苏省人民医院 顾艳宏

# 04摘要号：4050

Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases.

作者：山东省立医院 宋伟

# 05摘要号：4057

Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective single-arm phase II clinical trial.

作者：福建医科大学附属协和医院 陈椿

# 06摘要号：4093

SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.

作者：中国科学技术大学附属第一医院 刘连新

# 07摘要号：4161

First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.

作者：中国人民解放军总医院第五医学中心 戴广海

# 08摘要号：TPS4220

A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.

作者：江苏省人民医院 李相成

# 09摘要号：e14605

Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study.

作者：浙江大学医学院附属第一医院 梁廷波

# 10摘要号：e15525

The CREAFORMO-004 study: A phase II study of HR070803 plus 5-fluorouracil/leucovorin and bevacizumab as second-line treatment in patients with metastatic colorectal cancer.

作者：复旦大学附属肿瘤医院 邹建玲

# 11摘要号：e15633

Neoadjuvant therapy with mFOLFOXIRI combined with camrelizumab and bevacizumab for microsatellite stable, locally advanced rectal cancer: A single-arm, open-label phase II study.

作者：北京大学首钢医院 王晓东

#12摘要号：e16005

Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial.

作者：安阳市肿瘤医院 夏金

#13摘要号：e16017

HIPEC combined with camrelizumab, paclitaxel and S-1 for conversion therapy in patients with advanced gastric cancer with peritoneal metastasis: A prospective phase II clinical study.

作者：浙江省肿瘤医院 杜义安

#14摘要号：e16070

STAR-01: A randomized phase III clinical trial comparing PD-1 combined with apatinib and SOX，PD-1 combined with SOX, versus SOX alone in patients with advanced gastric adenocarcinoma.

作者：山东省立医院 李乐平

#15摘要号：e16114

A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC).

作者：四川大学华西医院 孙尚伟

#16摘要号：e16139

Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research.

作者：哈尔滨医科大学附属肿瘤医院 马建群

#17摘要号：e16141

Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study.

#18摘要号：e16143

Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study.

作者：河南科技大学第一附属医院 贾瑞诺

#19摘要号：e16147

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.

作者：山东第一医科大学附属肿瘤医院 王龙刚

# 20摘要号：e16202

Updated results of camrelizumab (Cam) plus low dose apatinib combined with gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract cancer (BTC): A single center, phase Ib/II trial.

作者：中山大学肿瘤防治中心 张东生

# 21摘要号：e16204

Real-world analysis of effectiveness in unresectable hepatocellular carcinoma patients treated with camrelizumab-based regimens.

作者：江苏省人民医院 夏永祥

#22摘要号：e16215

Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma.

作者：中国人民解放军总医院第五医学中心 曾珍

#23摘要号：e16229

Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: A prospective, single-arm, phase II study.

作者：中山大学肿瘤防治中心 高飞

#24摘要号：e16256

Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study.

作者：中山大学肿瘤防治中心 李少华

#25摘要号：e16279

Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial.

作者：江苏省人民医院 夏永祥

#26摘要号：e16284

Assessing comparative efficacies of camrelizumab as a single or combination therapy in patients with hepatocellular carcinoma: A systematic review and network meta-analysis.

作者：Khyber Teaching Hospital Osama Ahmad

#27摘要号：e16294

NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.

作者：江苏省人民医院 饶建华

#28摘要号：e16297

Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial.

作者：中山大学孙逸仙纪念医院 彭林辉

#29摘要号：e16299

Perioperative camrelizumab plus apatinib and gemcitabine-oxaliplatin in patients with borderline resectable biliary tract malignancies: A multicenter, single-arm, phase II trial.

作者：浙江大学医学院附属第一医院 单建贞

# 30摘要号：e16365

Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study.

作者：南京大学医学院附属盐城第一医院 李剑萍

（上下滑动查看更多）

乳腺癌领域：

原研创新药持续发力，赋能精准治疗新时代

在乳腺癌领域，吡咯替尼、达尔西利、卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、瑞康曲妥珠单抗（SHR-A1811）、SHR-2017，或产品间联合或联合化疗，共有19项研究入选（包括3项快速口头报道和7项壁报展示以及9项线上发表）。

其中，吡咯替尼精准靶向HER-2阳性乳腺癌，在本次 ASCO 年会上有 7 项研究入选。达尔西利作为高选择性CDK4/6 抑制剂，在HR+/HER2-乳腺癌治疗中的表现突出，本次有 6 项研究入选，两项创新药物持续发力，为广大患者带来更好的治疗效果和生活质量。

创新型HER2 ADC瑞康曲妥珠单抗（SHR-A1811）在HER2阳性、HER2低表达晚期乳腺癌领域展开积极探索并取得诸多亮眼成果，有望为广大患者带来全新治疗选择。本次ASCO大会中，其与阿得贝利单抗等药物多项研究入选快速口头报告，获得国际学术界广泛关注。

# 01摘要号：515

# 02摘要号：1017

# 03摘要号：1018

# 04摘要号：594

SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer: A single-arm, phase II clinical study.

作者：河南省肿瘤医院 刘真真

# 05摘要号：600

Biomarkers of neoadjuvant dalpiciclib in patients with operable HER2-negative luminal B breast cancer in the DANCER trial.

作者：浙江大学医学院附属第二医院 周云翔

# 06摘要号：1031

Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial).

作者：河北医科大学第四医院 宋振川

# 07摘要号：1101

Camrelizumab plus nab-paclitaxel and cisplatin as first-line treatment for metastatic triple-negative breast cancer: A prospective, single-arm, open-label phase II trial.

作者：复旦大学附属肿瘤医院 王碧芸

#08摘要号：1103

SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort.

作者：江苏省人民医院 梁艳

#09摘要号：12059

A phase 1b study of SHR-2017, a RANKL/NGF targeted antibody, in patients (pts) with breast cancer bone metastasis.

作者：北京大学肿瘤医院 梁旭

# 10摘要号：12069

Granisetron transdermal delivery system for nausea and vomiting prophylaxis in HER2-positive metastatic breast cancer patients receiving pyrotinib and capecitabine: A single-arm phase II study.

作者：复旦大学附属肿瘤医院 曹君

#11摘要号：e12593

Dalpiciclib combined with chidamide and letrozole as neoadjuvant therapy for HR-positive, HER2-negative early or locally advanced breast cancer: A single-arm, prospective, exploratory clinical study.

作者：安阳市肿瘤医院 史源

#12摘要号：e12609

Multicenter real-world study of trastuzumab combined with pirotinib or pertuzumab as a neoadjuvant therapy for stage II-III HER-2 positive breast cancer.

作者：陆军军医大学西南医院 周于钦

#13摘要号：e12623

Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for triple negative breast cancer (TNBC): A single-arm, prospective phase II study (MA-BC-II-026).

作者：四川大学华西医院 庄纯莹

#14摘要号：e13005

Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: A multicenter real-world study.

作者：中南大学湘雅二医院 易文君

#15摘要号：e13007

Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study.

作者：江苏省肿瘤医院 李诗怡

#16摘要号：e13016

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study.

作者：中国医学科学院肿瘤医院 李逸群

#17摘要号：e13060

Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase Ⅱ trial.

作者：天津市肿瘤医院 郝春芳

#18摘要号：e13062

Efficacy and safety of dalpiciclib plus toremifene in advanced HR-positive HER2-negative breast cancer as first-line treatment: A multicenter, single-arm phase II trial.

作者：天津市肿瘤医院 贾勇圣

#19摘要号：e13071

Dalpiciclib plus chidamide in HR+/HER2- advanced breast cancer following CDK4/6 inhibitor treatment failure: Final results of a phase Ib trial.

作者：中国人民解放军总医院第五医学中心 王涛

（上下滑动查看更多）

其他肿瘤领域：

全面布局，多点开花，中国创新药企彰显强劲综合实力

在肺癌、妇科肿瘤、淋巴瘤、膀胱癌、头颈肿瘤、黑色素瘤、肉瘤、鼻咽癌、脊索瘤、唾液腺癌、胸腺癌、硬纤维瘤、涎腺导管癌等其他多个疾病领域，卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、吡咯替尼、达尔西利、氟唑帕利、法米替尼、SHR-1501、瑞拉芙普-α（SHR-1701）、SHR-1826、瑞康曲妥珠单抗（SHR-A1811）、SHR-A1912、SHR-A2102等抗肿瘤创新药相关研究一共入选了4项口头报告、2项快速口头报告、12项壁报展示和4项线上发表，彰显了恒瑞医药强劲的研发实力和广泛影响力。此外，昂丹司琼口溶膜在防治化疗导致的恶心呕吐方面展现出了良好的疗效，本次ASCO年会有1项研究线上发表。

# 01摘要号：106

# 02摘要号：107

# 03摘要号：6006

# 04摘要号：11503

# 05摘要号：7013

# 06摘要号：9512

# 07摘要号：4606

IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.

作者：北京大学第一医院 陈宇珂

#08摘要号：5572

Safety and effectiveness of fuzuloparib in patients with ovarian cancer: A nationwide, multicenter, prospective real-world study.

作者：华中科技大学同济医学院附属同济医院 高庆蕾

#09摘要号：5612

SHR-A1811 in patients (pts) with HER2-expressing advanced gynecological cancers (Gynecol C): A phase 2 study.

作者：山东大学齐鲁医院 孔北华

# 10摘要号：6026

Cetuximab plus dalpiciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma.

作者：上海交通大学医学院附属第九人民医院 鞠侯雨

#11摘要号：6029

Retlirafusp alfa-a bifunctional anti-PD-L1/TGF-βRII agent plus nab-paclitaxel and carboplatin in pre-treated recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, phase II clinical trial.

作者：复旦大学附属肿瘤医院 季冬梅

#12摘要号：6030

Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial.

#13摘要号：6034

A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.

作者：中山大学孙逸仙纪念医院 何奕霖

# 14摘要号：8109

A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas.

作者：上海市胸科医院 许宁

#15摘要号：8548

Camrelizumab combined with 2 cycles of chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC): A two-arm, single-center, phase 2 study.

作者：南京医科大学第二附属医院 刘红兵

#16摘要号：10611

Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: 32-month follow-up from a single-center exploratory study.

作者：北京大学肿瘤医院 葛赛

#17摘要号：11037

Comprehensive analysis on reactive cutaneous capillary endothelial proliferation following camrelizumab-based therapy in patients with solid tumors: A large-scale pooled analysis of nine phase 2 or phase 3 registration trials.

作者：中国药科大学附属南京天印山医院秦叔逵

#18摘要号：11533

Phase ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma.

作者：中山大学肿瘤防治中心 王安琪

#19摘要号：e18005

Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study.

作者：上海交通大学医学院附属第九人民医院 任国欣

# 20摘要号：e18019

Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study.

作者：桂林医学院附属医院 蒋伟

# 21摘要号：e18148

A retrospective study of pyrotinib for advanced salivary duct carcinoma (SDC) with positive HER2 expression.

作者：浙江省肿瘤医院 纪青

# 22摘要号：e20589

First-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A nationwide, retrospective real-world study.

作者：山东省肿瘤医院 魏中慧

# 23摘要号：e24079

Real-world effectiveness and safety of ondansetron oral soluble film for the prevention of chemotherapy-induced nausea and vomiting.

参考文献：

1.https://meetings.asco.org/abstracts-presentations/search?query=*&q=2025 ASCO Annual Meeting

来源：壹生